Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.
Authors
Anastasia Danilova
Moscow City Oncology Hospital 62, Krasnogorskiy Rayon, Russian Federation
Anastasia Danilova , Daniil Stroyakovsky , Dmitry Kanner , Ilya Chernikovksy , Nikita Savelov , Mikhail Volkonsky , Irina Demidova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 141)
DOI
10.1200/JCO.2024.42.3_suppl.141
Abstract #
141
Poster Bd #
J7
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC).
First Author: Federico Innocenti
Poster
2016 ASCO Annual Meeting
Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.
First Author: Dominik Paul Modest
Poster
2016 ASCO Annual Meeting
Clinical correlation with codon-specific mutations in metastatic colorectal cancer.
First Author: Sophia C. Kamran
Poster
2016 Gastrointestinal Cancers Symposium
The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.
First Author: Tamer Garawin